Stay updated on IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial
Sign up to get notified when there's something new on the IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial page.

Latest updates to the IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange Detected- Added a government-operating-status notice and updated operating status links, and bumped revision to v3.2.0. - Removed a specific resource reference: Genetic and Rare Diseases Information Center resources: Primary biliary cholangitis (now outdated).SummaryDifference6%
- Check16 days agoChange DetectedThe page has updated the revision from v3.0.2 to v3.1.0, indicating a version upgrade.SummaryDifference0.1%
- Check23 days agoNo Change Detected
- Check31 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2. The 'Back to Top' link was removed; no other substantive changes were made.SummaryDifference0.3%
- Check38 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.3%
- Check45 days agoChange DetectedThe web page has been updated to include specific drug information related to Odevixibat and its availability for treating primary biliary cholangitis, along with a new facility name and location in Gothenburg, Sweden. However, several previous location-related terms and topics have been removed.SummaryDifference5%
- Check59 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial
Enter your email address, and we'll notify you when there's something new on the IBAT Inhibitor A4250 for Cholestatic Pruritus Clinical Trial page.